Anti-HPV6 L1 polyclonal antibody (CABT-B8785)


Host Species
Antibody Isotype
Species Reactivity


Application Notes
WB: 1:200-1000
ELISA: 1:200-2000
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.


Alternative Names
HPV; L1; major capsid L1 protein; HPV-6; HPV-6 capsid; HPV6 capsid protein


Have you cited CABT-B8785 in a publication? Let us know and earn a reward for your research.

Related Products

Custom Antibody Labeling

We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Impact of the Quadrivalent HPV6/11/16/18 Vaccine in Women Who have Undergone Definitive Therapy: Do These Women Benefit from Vaccination?


Authors: Huh, W.; Joura, E.; Garland, S.; Paavonen, J.; Ferris, D.; Sings, H.; James, M.; Haupt, R.

Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition


Authors: Handisurya, Alessandra; Lazar, Stefanie; Papay, Pavol; Primas, Christian; Haitel, Andrea; Horvat, Reinhard; Tanew, Adrian; Vogelsang, Harald; Kirnbauer, Reinhard

Patients receiving tumour necrosis factor alpha (TNF-alpha) inhibitors are at increased risk of exacerbation of (myco-)bacterial and some viral infections. However, information on anogenital human papillomavirus (HPV) infection in these patients is sparse or conflicting. In this study 222 patients with psoriasis or inflammatory bowel disease (IBD), who received either anti-TNF-alpha inhibitors or alternatives (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) continuously for at least 6 months, were evaluated for the presence of anogenital HPV-induced lesions, mucosal HPV DNA, and serological status of mucosal low-risk HPV6 and high-risk HPV16/HPV18. Hallmarks of anogenital HPV infection were more frequently detected in patients with psoriasis than in those with IBD. HPV-induced lesions, viral DNA, and seroprevalence were not elevated in participants with psoriasis or IBD, who received TNF-alpha inhibitors for a mean duration of 31.4 months (range 6-96 months) compared with recipients of alternative or no treatment. TNF-alpha blockade for a mean period of 31.4 months does not increase detectable anogenital HPV infection or disease.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket